Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 5:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: molecular genetic technique Clear all
Completed Phase 2 Interventional Results available

Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma

NCT00498927
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, protein expression analysis, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis, immunoenzyme technique
Drug · Genetic · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Sep 28, 2026, 5:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

NCT00389805
View directory record Official record
Conditions
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, pemetrexed disodium, gene expression analysis, mutation analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, flow cytometry, immunoenzyme technique, immunohistochemistry staining method
Drug · Genetic · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 120 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Sep 28, 2026, 5:09 PM EDT
Completed No phase listed Observational

United States Hypophosphatasia Molecular Research Center

NCT05062629
View directory record Official record
Conditions
Hypophosphatasia
Interventions
Whole Genome Sequencing
Genetic
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 28, 2026, 5:09 PM EDT
Not listed No phase listed Observational

Age-related Macular Degeneration (AMD) and Cardiovascular Disease

NCT04087356
View directory record Official record
Conditions
Age-related Macular Degeneration, Coronary Artery Disease, Cardiovascular Diseases
Interventions
Blood draw
Genetic
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
50 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 28, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Results available

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

NCT01270880
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
Hsp90 inhibitor STA-9090, laboratory biomarker analysis, polymerase chain reaction, enzyme-linked immunosorbent assay, RNA analysis, spectrophotometry, reverse transcriptase-polymerase chain reaction, gene expression analysis
Drug · Other · Genetic
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Baltimore, Maryland • Detroit, Michigan • Piscataway, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Sep 28, 2026, 5:09 PM EDT
Completed No phase listed Observational

Study of Proteins in Head and Neck Cancer Cells

NCT00896948
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Southern blotting, TdT-mediated dUTP nick end labeling assay, gene expression analysis, protein expression analysis, flow cytometry, fluorescent antibody technique, immunoenzyme technique, immunohistochemistry staining method, immunologic technique
Genetic · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 28, 2026, 5:09 PM EDT
Enrolling by invitation Not applicable Interventional

Genome Sequencing in the Intensive Care Unit Population

NCT04848090
View directory record Official record
Conditions
Infant, Newborn, Disease, Genetic Disease
Interventions
Neonate WGS Testing
Diagnostic Test
Lead sponsor
Jerry Vockley, MD, PhD
Other
Eligibility
Up to 1 Year
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 28, 2026, 5:09 PM EDT
Completed Not applicable Interventional Results available

Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients With Advanced Cancer

NCT02823652
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Locally Advanced Malignant Neoplasm
Interventions
standard genetic education, Genetic Counseling, Genetic Testing, Internet-Based Intervention, Survey Administration
Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 28, 2026, 5:09 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients

NCT06659458
View directory record Official record
Conditions
Lung Cancer - Non Small Cell, EGFR Exon 19 Deletion Mutation
Interventions
blood draw, Gene sequencing
Other
Lead sponsor
Our Lady of the Lake Hospital
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Sep 28, 2026, 5:09 PM EDT
Completed Phase 1 Interventional Results available

Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors

NCT01206465
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pralatrexate, fluorouracil, laboratory biomarker analysis, DNA analysis, high performance liquid chromatography, polymerase chain reaction, nucleic acid sequencing, pharmacological study, pharmacogenomic studies, polymorphism analysis
Drug · Other · Genetic
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced Sep 28, 2026, 5:09 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Identifying and Caring for Individuals With Inherited Cancer Syndrome

NCT04494945
View directory record Official record
Conditions
BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome, Breast Ductal Carcinoma In Situ, Hematopoietic and Lymphoid System Neoplasm, Hereditary Neoplastic Syndrome, Lynch Syndrome, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Genetic Counseling, Genetic Testing, Survey Administration
Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
27,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 28, 2026, 5:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept

NCT02291887
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Ranibizumab, Aflibercept
Drug
Lead sponsor
Associated Retinal Consultants, Michigan
Other
Eligibility
40 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 28, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Vitamin D Supplementation in RNA-seq Profiles of Single-core Prostate Samples, Among Veterans

NCT04621500
View directory record Official record
Conditions
Prostate Cancer, Vitamin D Deficiency, Stress Reaction
Interventions
cholecalciferol, Standard of Care Prostate Biopsy - collection of 13th core for RNA-seq, Standard of Care Prostate Biopsies at baseline and after one year vitamin D3 supplementation, Allostatic Load
Drug · Procedure · Diagnostic Test
Lead sponsor
Medical University of South Carolina
Other
Eligibility
50 Years to 75 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Sep 28, 2026, 5:09 PM EDT
Completed No phase listed Observational

Studies of Families With Hereditary Cataracts

NCT00001609
View directory record Official record
Conditions
Cataract, Congenital Anomaly
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 28, 2026, 5:09 PM EDT
Recruiting Not applicable Interventional

Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma

NCT05281731
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
Sonobiopsy, Research blood, Cancer Personalized Profiling, Definity®
Device · Procedure · Genetic
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 28, 2026, 5:09 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

DNA Analysis of Blood and Tissue from Patients with Lung Cancer

NCT00471978
View directory record Official record
Conditions
Lung Cancer
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 28, 2026, 5:09 PM EDT
Completed No phase listed Observational

Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma

NCT00003863
View directory record Official record
Conditions
Lymphoma
Interventions
comparative genomic hybridization, cytogenetic analysis, fluorescence in situ hybridization, gene rearrangement analysis
Genetic
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
69
States / cities
Anniston, Alabama • La Jolla, California • San Diego, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Sep 28, 2026, 5:09 PM EDT
Completed Not applicable Interventional

DNA Changes That Affect Vitamin D Metabolism in Patients With Colorectal Cancer Receiving Vitamin D Supplements

NCT00550563
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cholecalciferol, polymerase chain reaction, polymorphism analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, adjuvant therapy, immunoscintigraphy
Dietary Supplement · Genetic · Other + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 28, 2026, 5:09 PM EDT
Completed Phase 1 Interventional

Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer

NCT00379509
View directory record Official record
Conditions
Breast Cancer
Interventions
lapatinib ditosylate, TdT-mediated dUTP nick end labeling assay, gene expression analysis, microarray analysis, immunohistochemistry staining method, biopsy, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 28, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck

NCT00720304
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
docetaxel, erlotinib hydrochloride, fluorescence in situ hybridization, polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, therapeutic conventional surgery, intensity-modulated radiation therapy, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Sep 28, 2026, 5:09 PM EDT
Completed Phase 1 Interventional

Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients

NCT00708448
View directory record Official record
Conditions
Cancer, Non Small Cell Lung Cancer
Interventions
PET Imaging, Erlotinib, Bevacizumab
Radiation · Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 28, 2026, 5:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neulasta in Type 1 Diabetes

NCT00662519
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Neulasta (Pegylated), Placebo, Mixed Meal Tolerance Test (MMTT), Blood test, DNA Test
Drug · Dietary Supplement · Other
Lead sponsor
University of Florida
Other
Eligibility
12 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Sep 28, 2026, 5:09 PM EDT
Terminated No phase listed Observational

Genetics of Motor Learning

NCT01105845
View directory record Official record
Conditions
Parkinson s Disease, Dystonic Disorders, Focal Dystonia, Movement Disorders
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Sep 28, 2026, 5:09 PM EDT
Completed Phase 1 Interventional

Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

NCT00598169
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bortezomib, carboplatin, dexamethasone, etoposide, ifosfamide, polymerase chain reaction, western blotting
Biological · Drug · Genetic
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Sep 28, 2026, 5:09 PM EDT